CN102648180A - G蛋白偶联受体88的调节剂 - Google Patents

G蛋白偶联受体88的调节剂 Download PDF

Info

Publication number
CN102648180A
CN102648180A CN2010800560408A CN201080056040A CN102648180A CN 102648180 A CN102648180 A CN 102648180A CN 2010800560408 A CN2010800560408 A CN 2010800560408A CN 201080056040 A CN201080056040 A CN 201080056040A CN 102648180 A CN102648180 A CN 102648180A
Authority
CN
China
Prior art keywords
alkyl
methyl
alkoxy
butyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800560408A
Other languages
English (en)
Chinese (zh)
Inventor
毕英智
C.D.德齐尔巴
J.J.布隆森
C.芬克
M.格林
D.金博尔
J.E.马科
S.权
Y.张
G.齐普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Lexicon Pharmaceuticals Inc
Original Assignee
Bristol Myers Squibb Co
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Lexicon Pharmaceuticals Inc filed Critical Bristol Myers Squibb Co
Publication of CN102648180A publication Critical patent/CN102648180A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN2010800560408A 2009-10-09 2010-10-06 G蛋白偶联受体88的调节剂 Pending CN102648180A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25009109P 2009-10-09 2009-10-09
US61/250,091 2009-10-09
PCT/US2010/051597 WO2011044212A1 (en) 2009-10-09 2010-10-06 Modulators of g protein-coupled receptor 88

Publications (1)

Publication Number Publication Date
CN102648180A true CN102648180A (zh) 2012-08-22

Family

ID=43479451

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800560408A Pending CN102648180A (zh) 2009-10-09 2010-10-06 G蛋白偶联受体88的调节剂

Country Status (6)

Country Link
US (1) US8426414B2 (https=)
EP (1) EP2486014B1 (https=)
JP (1) JP2013507371A (https=)
CN (1) CN102648180A (https=)
ES (1) ES2430946T3 (https=)
WO (1) WO2011044212A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497271B2 (en) 2009-10-07 2013-07-30 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8304577B2 (en) 2009-10-09 2012-11-06 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
EP3019475A1 (en) 2013-07-08 2016-05-18 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
EP3054955B1 (en) 2013-10-11 2018-05-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
MX2020009950A (es) 2018-03-23 2021-04-28 Carmot Therapeutics Inc Moduladores de receptores acoplados a proteina g.
JP2023550643A (ja) * 2020-11-25 2023-12-04 レネオ ファーマシューティカルズ，インク． Ｐｐａｒデルタアゴニストの製造方法
US20240132450A1 (en) 2020-12-17 2024-04-25 Acadia Pharmaceuticals Inc. Modulators of g protein-coupled receptor 88
US12281149B2 (en) 2021-05-13 2025-04-22 Carmot Therapeutics, Inc. Modulators of G-protein coupled receptors
GB202209195D0 (en) 2022-06-22 2022-08-10 Pandeia Therapeutics Ltd Modulators of g protein-coupled receptor 88
GB202209193D0 (en) 2022-06-22 2022-08-10 Pandeia Therapeutics Ltd Modulators of g protein-coupled receptor 88
WO2026055419A1 (en) 2024-09-05 2026-03-12 Acadia Pharmaceuticals Inc. Modulators of g protein-coupled receptor 88

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027252A1 (en) * 2004-09-10 2006-03-16 Ucb Pharma, Sa Sigma receptor ligands
WO2006066896A2 (en) * 2004-12-23 2006-06-29 Novartis Ag Pyrrolidine derivatives for the treatment of a disease depending on the activity of renin

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ257955A (en) 1992-12-02 1996-05-28 Pfizer Catechol diethers pharmaceutical compositions
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
DE60319686T2 (de) 2002-04-05 2009-04-16 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Cyanamide als reversible hemmer von cystein proteasen
WO2003103666A2 (en) 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
WO2004047738A2 (en) 2002-11-22 2004-06-10 Bristol-Myers Squibb Company Arylcyclopropylcarboxylic amides as potassium channel openers
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
US7601868B2 (en) 2003-02-12 2009-10-13 Takeda Pharmaceutical Company Limited Amine derivative
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
WO2006012227A2 (en) 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
JP2007217408A (ja) 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd 医薬組成物
NZ571803A (en) 2006-04-07 2011-12-22 Vertex Pharma Amide indole derivatives as modulators of ATP-binding cassette transporters
WO2007129188A1 (en) 2006-05-10 2007-11-15 Pfizer Japan Inc. Cyclopropanecarboxamide compound
US20080039535A1 (en) 2006-08-14 2008-02-14 Wyeth Methods of identifying agents for treating neurological disorders
US8497271B2 (en) 2009-10-07 2013-07-30 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8304577B2 (en) 2009-10-09 2012-11-06 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027252A1 (en) * 2004-09-10 2006-03-16 Ucb Pharma, Sa Sigma receptor ligands
WO2006066896A2 (en) * 2004-12-23 2006-06-29 Novartis Ag Pyrrolidine derivatives for the treatment of a disease depending on the activity of renin

Also Published As

Publication number Publication date
US8426414B2 (en) 2013-04-23
US20110251204A1 (en) 2011-10-13
JP2013507371A (ja) 2013-03-04
ES2430946T3 (es) 2013-11-22
EP2486014B1 (en) 2013-07-31
WO2011044212A1 (en) 2011-04-14
EP2486014A1 (en) 2012-08-15

Similar Documents

Publication Publication Date Title
CN102648180A (zh) G蛋白偶联受体88的调节剂
CA2168432C (en) Piperazine compounds used in therapy
US8497271B2 (en) Modulators of G protein-coupled receptor 88
US9487494B2 (en) Cyclic hydrocarbon compounds for the treatment of diseases
US8304577B2 (en) Modulators of G protein-coupled receptor 88
UA82853C2 (en) Carboxamide compounds having an mch-antagonistic effect, medicaments containing said compounds, and methods for the production thereof
CA2853006A1 (en) Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection
CN107922391B (zh) 吡啶和嘧啶衍生物
CN101321529A (zh) 作为抗肿瘤剂的二芳基醚衍生物
KR20230104191A (ko) 질환 치료를 위한 이환식 화합물 및 그 용도
WO2023114456A1 (en) Uses of bicyclic compounds for the treatment of diseases
HK40113746A (zh) 双环化合物用於治疗疾病的用途
HK40122844A (zh) 用於治疗疾病的双环化合物及其用途
WO2023215376A1 (en) Methods of treating neuropathies
HK40097563A (zh) 用於治疗疾病的双环化合物及其用途
CN118382441A (zh) 双环化合物用于治疗疾病的用途
JP2010538055A (ja) 二環式アリールおよびヘテロアリール受容体モジュレーター
EA049703B1 (ru) Бициклические соединения и их применение для лечения заболеваний
HK1251226B (zh) 吡啶和嘧啶衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20120822

C20 Patent right or utility model deemed to be abandoned or is abandoned